Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	4,609	7,093	5,718	4,127	4,332	1,956
Market Cap Growth	-3.45%	24.06%	38.54%	-4.73%	121.45%	163.70%
Enterprise Value	4,392	6,852	5,278	3,635	3,831	1,761
PE Ratio	-	-13.42	-8.77	-5.53	-12.56	-6.42
PS Ratio	8.80	17.89	75.81	62.01	17.28	-
PB Ratio	17.28	36.47	33.66	20.78	21.18	57.15
P/FCF Ratio	-12.87	-11.91	-11.10	-7.31	-26.11	-9.19
P/OCF Ratio	-12.88	-11.93	-11.13	-7.33	-26.99	-9.27
EV/Sales Ratio	8.38	17.28	69.97	54.62	15.28	-
EV/EBITDA Ratio	-17.87	-13.84	-8.55	-4.97	-12.27	-5.89
EV/EBIT Ratio	-17.79	-13.79	-8.53	-4.96	-12.24	-5.88
EV/FCF Ratio	-12.47	-11.51	-10.24	-6.44	-23.09	-8.28
Debt / Equity Ratio	0.41	0.57	0.66	1.06	1.85	4.59
Debt / EBITDA Ratio	-0.28	-0.22	-0.18	-0.29	-1.21	-0.53
Debt / FCF Ratio	-0.20	-0.19	-0.22	-0.37	-2.28	-0.74
Quick Ratio	2.76	2.26	3.35	5.40	6.85	5.35
Current Ratio	3.77	3.10	4.29	6.25	7.15	5.67
Asset Turnover	0.63	0.45	0.08	0.09	0.31	0
Interest Coverage	-13.31	-16.80	-18.97	-55.34	-10.46	-56.66
Return on Equity (ROE)	-160.70%	-178.50%	-204.80%	-5796.70%	-172.10%	-218.60%
Return on Assets (ROA)	-49.80%	-60.40%	-69.00%	-102.30%	-42.00%	-81.80%
Return on Capital (ROIC)	-107.53%	-169.30%	-210.42%	-131.16%	-36.70%	-150.59%
Earnings Yield	-9.05%	-7.45%	-11.41%	-18.08%	-7.96%	-15.58%
FCF Yield	-11.95%	-8.39%	-9.01%	-13.67%	-3.83%	-10.88%
Buyback Yield / Dilution	-7.98%	-11.84%	-25.70%	-12.32%	-20.78%	-14.40%
Total Shareholder Return	-7.98%	-11.84%	-25.70%	-12.32%	-20.78%	-14.40%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).